Trial Information
Summary: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Status: Completed
Protocol Number: BC20688
Sponsor: Hoffmann-La Roche
Company Division: Pharmaceutical
Official Scientific Title: A double blind, placebo-controlled, dose-ranging study to investigate the effect on glycemic control, safety, pharmacokinetics and pharmacodynamics of GLP-1 in patients with type 2 diabetes mellitus treated with a stable dose of metformin.
Brief Summary: This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals. Target sample size is 264.
Study Phase: II
Study Design / Study Details:
- Purpose: Treatment
- Allocation: Randomized
- Masking: Double Blind
- Control: Placebo
- Assignment: Parallel
- Endpoints: Safety/Efficacy
Study Type:
Interventional
Condition: Diabetes Mellitus, Type 2
Intervention Type: Drug
Intervention Name: GLP-1
Primary Outcome: 1. Absolute change from baseline in HbAlc Time frame: Week 8
Key Secondary Outcomes: 1. Absolute change from baseline in FPG, fructosamine, body weight, fasting insulin, C-peptide, glucagon. Time frame: Week 8
2. Changes in lipid profile Time frame: Week 8
3. AEs, laboratory parameters, primary pharmacokinetic parameters Time frame: Throughout study
Inclusion Criteria:
- adult patients, 18-75 years of age;
- type 2 diabetes mellitus, with stable metformin treatment for >=3 months;
- stable weight +/-10% for >=3 months before screening.
Exclusion Criteria:
- type 1 diabetes mellitus;
- treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months;
- use of weight-lowering medications in the last 3 months;
- uncontrolled hypertension.
Gender: Males or Females
Age Limits: Min: 18 Years Max: 75 Years
Accepts Healthy Volunteers: No
Trial Registration Date: 01/17/2007
Date Last Updated: 06/17/2008
Link To Trial Results
|
Contact:
Research Site:
Located In:
Sofia, Bulgaria, 1113
Telephone: 973-235-5000 or 800-526-6367
|
|

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: July 7, 2008 at 2:40:19 PM